Our Team
Founded by Flagship Pioneering, Montai’s leadership team has a track record of building high-performing teams and high-impact companies.
We are a mission-aligned team with expertise across human biology, immunology, natural products chemistry, formulations, computational biology, data science, machine learning, drug development, clinical, and commercial leadership.
Our Purpose
We are drawn together by our shared purpose and relentless hunger to improve health outcomes for as many people as possible while reducing the growing chronic disease burden. Our approach to innovation is uniquely human-centered — unlocking Anthromolecule connections to biological pathways driving disease and creating solutions preferred by patients and clinicians that are designed to slow, halt, or preempt disease.
We have brought together an inclusive, interdependently ambitious, and high-performing team with the courage to learn, iterate and make leaps together. We approach our work with humility, acknowledging and embracing the complexity of the disciplines we need to bring together and the many unknowns in human biology.
Board of Directors
-
Lord Ara Darzi, M.D.
Chair of the BoardDirector of the Institute of Global Health Innovation at Imperial College London and Chair of Imperial College Health Partners; Honorary Consultant Surgeon at Imperial College Hospital NHS Trust -
Noubar Afeyan, Ph.D.
Co-Founder and Board DirectorFounder & CEO, Flagship Pioneering -
Ignacio Martinez
Co-Founder and Board DirectorGeneral Partner, Flagship Pioneering -
Margo Georgiadis
Co-Founder and CEO; Board Director -
Phyllis Yale
Board DirectorChair of the Board, Blue Cross Blue Shield of Massachusetts and Kindred Healthcare, Inc.; Board Member, Bristol-Myers Squibb; Former Senior Partner and Leader of Healthcare Practice, Bain & Company -
Jim Gilbert
Board ObserverSenior Partner, Flagship Pioneering; Former Partner and Managing Director of Global Healthcare Practice, Bain & Company -
Michael Severino, M.D.
Board DirectorCEO, Tessera Therapeutics; Former Vice Chairman and President, Abbvie; Former SVP and CMO, Amgen -
Andreas Fibig
Board DirectorFormer Chairman and CEO, International Flavors & Fragrances; Former Chairman and President, Bayer Healthcare Pharmaceuticals
Our Advisors
-
Peter Hutt
Former Chief Counsel, FDA; Senior Counsel, Covington & Burlington LLP; Member, National Academy of Medicine -
Jim Karkanias, Ph.D.
CTO, Chan Zuckerberg Biohub; Former GM, Data Platform Group, Microsoft; Former Executive Director, Merck -
Iain McInnes, Ph.D., M.B.Ch.B
Vice Principal and Head of College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine, Versus Arthritis Professor of Rheumatology, University of Glasgow -
Paul Navarre
Chairman, HTL; Chairman, Arkopharma; Board Member, LEO Pharma; Former CEO, Ferring Pharmaceuticals; Former President of International Operations and EAME, Allergan -
Jose Ordovas, Ph.D.
Professor and Leader of the Nutrition and Genomics Team at USDA Human Nutrition Research Center on Aging, Tufts University -
Paul Ridker, M.D.
Professor of Medicine, Harvard University and Brigham and Women's Hospital; Expert in inflammation and cardiovascular disease; Pioneered clinical research proving inflammation hypothesis in atherosclerosis, coronary artery disease, and more -
Luciano Rosetti, M.D.
CMO, Flagship Pioneering; Head of R&D, Pioneering Medicines; Former Global Head of R&D, Merck KGaA and Merck & Co. -
Luisa Salter-Cid, Ph.D.
CSO, Pioneering Medicines; Former CSO at Gossamer Bio; Head of Immunology, Small Molecule Immuno-Oncology, and Genomics Discovery, BMS -
Peter Sorger, Ph.D.
Otto Krayer Professor of Systems Pharmacology, Head of the Harvard Program in Therapeutic Sciences (HiTS), Harvard Medical School; Cofounder, Merrimack Pharmaceuticals -
Pietro Antonio Tataranni, M.D.
Chief Medical Officer, PepsiCo; Former SVP, Head of Medical Affairs, Diabetes and Cardiovascular, Sanofi -
Jing-Ke Weng, Ph.D.
Co-Founder, Double Rainbow Biosciences; Associate Professor of Biology, MIT; Member, Whitehead Institute for Biomedical Research
Join Us
Contact Us
-
Partnerships
We welcome the opportunity to partner with experts across areas who share our passion for creating Anthromolecule medicines and want to collaborate to accelerate the development of safe, efficacious and accessible therapies across diseases.
partnerships@montai.com -
Press
For media inquiries or the latest on research, thought leadership, company news, and events contact:
press@montai.com